액체생검 시장 : 샘플 종류, 기술(다중유전자 병렬 분석, 단일유전자 분석), 바이오마커, 용도, 기술, 지역별 분석, 점유율, 동향, 규모, 예측(2020-2026년)
Liquid Biopsy Market, by Sample Type, By Technology (Multi-gene-parallel Analysis, and Single Gene Analysis ), By Biomaker, By Application, By Technology, and By Geography - Analysis, Share, Trends, Size, & Forecast From 2020 - 2026
상품코드 : 941384
리서치사 : AnalystView Market Insights
발행일 : 2020년 06월
페이지 정보 : 영문 198 Pages
US $ 3,250 ₩ 3,839,000
PDF by E-mail (Single User Licence) help
1명만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 4,650 ₩ 5,493,000
PDF by E-mail (5 User Licence) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. 인쇄 횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,650 ₩ 6,674,000
PDF by E-mail (Enterprise User Licence) help
동일 기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 및 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다.
자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



한글목차

세계의 액체생검 시장은 2019년에 4,972만 달러를 기록했습니다. 시장은 2020-2026년의 예측기간 중 14.6%의 CAGR로 성장할 전망입니다.

세계의 액체생검(Liquid Biopsy) 시장에 대해 조사했으며, 시장 기회와 동향, 성장 촉진요인 및 억제요인, 샘플 종류·기술·바이오마커·용도·지역별 시장 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 시장 개요

제2장 주요 요약

제3장 주요 시장 동향

제4장 업계 조사

제5장 시장 상황

제6장 시장 분석 : 샘플 종류별

제7장 시장 분석 : 기술별

제8장 시장 분석 : 바이오마커별

제9장 시장 분석 : 용도별

제10장 시장 분석 : 지역별

제11장 벤더 분석

제12장 애널리스트의 견해

제13장 부록

KSM 20.06.24
영문 목차

영문목차

REPORT HIGHLIGHT

Liquid biopsy Market was valued at USD 49.72 million by 2019, growing with 14.6% CAGR during the forecast period, 2020-2026

Market Dynamics

Liquid biopsy is a non-invasive and easy method used to diagnose onset of cancer. Liquid biopsy is also called as fluid phase biopsy or fluid biopsy. With liquid biopsy tumors and mutations can be easily tracked over a period of time. For cancer treatment, safety and efficiency is improved by the use of these tests because of their ability to predict treatment outcome, execute apt therapeutic targets, and characterize new lesions.

The growing number of patients being diagnosed with several types of cancer and the advantages of liquid biopsy such as metastatic relapse and minimally invasive are the major factors driving the growth of global liquid biopsy market. According to World Health Organization (WHO), cancer is the second leading cause of death all over the world. Around 9.6 million deaths in 2018 were due to various types of cancer. Moreover, minimally invasive therapies are highly preferred by patients and a surge in disposable income is also witnessed among cancer patients, which is anticipated to propel the market growth during the forecast period. In addition, an increase in healthcare expenditure in the emerging economies such as China and India and growing use of biopsy tests are likely to create lucrative opportunities in the global industry. However, unclear regulation & reimbursement scenario and availability of alternatives to liquid biopsies are predicted to restrict the market growth in the coming future.

Sample Type Takeaway

Blood sample-based is anticipated to grow at a significant rate during the forecast period owing to numerous methods for purification and preexisting applications. Microvesicles, exosomes, circulating tumor cells, and cell-free DNA can be detected in blood samples. In the saliva-based sample type, the next generation sequencing technology is used for detecting multiple mutations in multiple genes. As per certain studies plasma and saliva measurements are corelated, which potentially presents that detection of oncogenic gene mutations.

Biomarker Takeaway

CTC biomarkers segment is estimated to hold the largest market share in the forecast period owing to accurate tracking results and high awareness levels of cancerous cells in the human body. The number of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) based liquid biopsy tests that are commercialized are 8-10. The CTC tests are applicable through biochemical marker analysis for classification of tumor cells through. CTC detection, isolation, and molecular characterization systems find tentative application in pancreatic, prostate, colon, breast, head, skin, neck, and lung cancer.

TECHNOLOGY TAKEAWAY

The multi-gene-parallel analysis (NGS) segment is expected to subjugate the worldwide market owing to its capability to denote diagnosis of multiple diseases at one time. Clinical pharmacogenomics tests are taken away by multigene tests from conventional sequencing of single genes, which is marked as a noteworthy step towards detailed analysis of cancer genome. This technology helps oncologists in guiding patients to the targeted therapy by detecting the genetic aberrations. On the other hand, the single gene analysis-based or PCR-based sequencing is employed for analyzing mutations in particular genes with the help of NGS multiplex testing.

Application Takeaway

The therapy selection for metastatic breast cancer segment is anticipated to witness a considerable growth in the estimated period owing to growing prevalence of metastatic caner all across the globe. It is estimated that liquid biopsy will find application in the molecular monitoring diagnostic, which can be investigated using various biofluids such as saliva, urine, CSF, and blood for patient screening during the forecast period.

REGIONAL TAKEAWAY

Presently, the North America region dominated the global liquid biopsy market in 2018 owing to increasing incidence of cancer and growing need for screening in this region. Europe is estimated to be the second-largest market due to recent regulatory CE approvals for commercial use of liquid biopsy tests.

Key Vendors Takeaway

The major players functioning in the global market are applying several strategies such as mergers & acquisitions and product launches to increase their market share. Some of the prominent players include Guardant Health, Biocept, Personal Genome Diagnostics, Adaptive Biotechnologies, NeoGenomics Laboratories, Cynvenio, Qiagen, RainDance Technologies, and Trovagene.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year - 2015 to 2018

Base Year - 2019

Estimated Year - 2020

Projected Year - 2026

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Government and Regional Agencies

Research Organizations

Consultants

Distributors

Scope of the Report

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LIQUID BIOPSY MARKET KEY PLAYERS

NeoGenomics Laboratories

Guardant Health

Biocept

Cynvenio

Qiagen

RainDance Technologies

Adaptive Biotechnologies

Personal Genome Diagnostics

Trovagene

GLOBAL LIQUID BIOPSY MARKET, BY SAMPLE TYPE

Urine Sample-based

Blood Sample-based

Other Biofluids

GLOBAL LIQUID BIOPSY MARKET, BY TECHNOLOGY

Multi-gene-parallel Analysis (NGS)

Single Gene Analysis (PCR Microarrays)

GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER

Circulating Tumor DNA (ctDNA)

Circulating Tumor Cells (CTC)

Exosomes

GLOBAL LIQUID BIOPSY MARKET, BY APPLICATION

Molecular Health Monitoring

Therapy Selection for Metastatic Breast Cancer (MBS)

Therapy Selection for Other Metastatic Cancer

GLOBAL LIQUID BIOPSY MARKET, BY REGION

North America

The U.S.

Canada

Europe

Germany

France

Italy

Spain

United Kingdom

Rest of Europe

Asia Pacific

India

China

South Korea

Japan

Singapore

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

Middle East and Africa

Saudi Arabia

United Arab Emirates

Rest of MEA

TABLE OF CONTENT

1. LIQUID BIOPSY MARKET OVERVIEW

2. EXECUTIVE SUMMARY

3. LIQUID BIOPSY KEY MARKET TRENDS

4. LIQUID BIOPSY INDUSTRY STUDY

5. LIQUID BIOPSY MARKET LANDSCAPE

6. LIQUID BIOPSY MARKET - BY SAMPLE TYPE

7. LIQUID BIOPSY MARKET - BY TECHNOLOGY

8. LIQUID BIOPSY MARKET - BY BIOMAKER

9. LIQUID BIOPSY MARKET - BY APPLICATION

10. LIQUID BIOPSY MARKET- BY GEOGRAPHY

11. KEY VENDOR ANALYSIS

12. 360 DEGREE ANALYSTVIEW

13. APPENDIX

(주)글로벌인포메이션 02-2025-2992 koreainfo@gii.co.jp
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기